






AREA OF THERAPY	PRECLINICAL	PHASE I	PHASE II	PHASE III	COMMERCIAL RIGHTS
<b>HEMATOLOGIC MALIGNANCIES</b>					
Multiple Myeloma Relapsed/refractory   BOSTON		SELINEXOR + VELCADE <sup>1</sup>			
Penta-refractory   STORM		SELINEXOR <sup>2</sup>			
Relapsed/refractory and front-line   STOMP		SELINEXOR + BACKBONE THERAPIES <sup>3</sup>			
Diffuse Large B-cell Lymphoma   SADAL		SELINEXOR			
<b>SOLID TUMOR MALIGNANCIES</b>					
Liposarcoma   SEAL		SELINEXOR			 Japan*
Endometrial Cancer   SIENDO <sup>4</sup>		SELINEXOR			
Glioblastoma   KING		SELINEXOR			 ANTENGENE China**
<b>ADDITIONAL ONCOLOGY PROGRAMS</b>					
MDS, CRC, PrC		ELTANEXOR			 ANTENGENE China***
Solid Tumors & Lymphoma		KPT-9274			
<b>OTHER INDICATIONS</b>					
Lymphoma in Companion Animals		VERDINEXOR			 ANIVIVE**** LIFESCIENCES

These investigational agents have not been approved for use by the FDA or any other regulatory agency.

1 Oral selinexor, Velcade® (bortezomib) and dexamethasone vs. Velcade and dexamethasone

2 Oral selinexor + dexamethasone

3 Oral selinexor and dexamethasone + Revlimid® (lenalidomide), Pomalyst® (pomalidomide), Velcade, Kyprolis® (carfilzomib) or Darzalex® (daratumumab)

4 Investigator-sponsored randomized Phase III trial

\*Ono licensed rights to selinexor and eltanexor in the following territories: Japan, S. Korea, Taiwan, Hong Kong, and ASEAN countries

\*\* Antengene licensed rights to selinexor and eltanexor in China and Macau

\*\*\* Antengene licensed rights to KPT-9274 and verdinexor in mainland China, Macau, Taiwan, Hong Kong, South Korea, and the ASEAN countries

\*\*\*\*Anivive holds exclusive worldwide rights to research, develop and commercialize verdinexor only for the treatment of cancer in companion animals